Charles River Laboratories (CRL)
Net profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Net income | US$ in thousands | 474,624 | 486,226 | 390,982 | 364,304 | 252,019 |
Revenue | US$ in thousands | 4,082,940 | 4,098,090 | 3,457,220 | 2,939,570 | 2,582,040 |
Net profit margin | 11.62% | 11.86% | 11.31% | 12.39% | 9.76% |
December 31, 2023 calculation
Net profit margin = Net income ÷ Revenue
= $474,624K ÷ $4,082,940K
= 11.62%
Charles River Laboratories' net profit margin has shown some variability over the past five years. In 2019, the company had a net profit margin of 9.76%, which increased to 12.39% in 2020, reflecting improved profitability. However, the margin declined slightly to 11.31% in 2021 before increasing again to 11.86% in 2022. In the most recent period of December 31, 2023, the net profit margin stands at 11.62%. Overall, the company has demonstrated relatively stable net profit margins hovering around the 11-12% range, indicating consistent profitability levels over the past five years.
Peer comparison
Dec 31, 2023
Company name
Symbol
Net profit margin
Charles River Laboratories
CRL
11.62%
Arrowhead Pharmaceuticals Inc
ARWR
-92.30%
Exelixis Inc
EXEL
11.35%
Incyte Corporation
INCY
16.18%
IQVIA Holdings Inc
IQV
9.49%
Medpace Holdings Inc
MEDP
15.01%